// Biotech and Pharma Therapeutics
HarmonyCares Deploys athenaOne® to Enhance In-Home Primary Care
July 22, 2025 / in-home care / value-based care / electronic health records / athenahealth / patient outcomes
HarmonyCares has implemented athenaOne® to streamline in-home primary care, enhance care team collaboration, and optimize financial operations—improving outcomes for complex patients through AI-enabled EHR, RCM, and analytics across its expanding value-based care network.
6 Health Systems that Faced Worker Strikes This Month
July 22, 2025 / healthcare strikes / nurse staffing / patient safety / labor negotiations / unionized healthcare
Healthcare worker strikes across six U.S. systems in July spotlight urgent concerns over unsafe staffing, poor labor practices, and risks to patient care—amplifying nationwide calls for fair wages, contract transparency, and stronger protections in clinical environments.
New genetic test predicts obesity before you start kindergarten
July 23, 2025 / genetic testing / childhood obesity / polygenic risk score / early intervention / obesity prediction
Researchers developed a polygenic risk score that predicts obesity risk from early childhood using data from over five million individuals, enabling earlier interventions and offering twice the predictive power of previous methods, with significant implications for public health strategies.
Ovagen breakthrough boosts yellow fever vaccine yields
July 23, 2025 / yellow fever / vaccine manufacturing / germ-free eggs / Ovagen / antimicrobial resistance
Ovagen’s germ-free egg technology boosts yellow fever vaccine yields 18-fold per egg, reduces antibiotic use, and may help close a 60-million-dose global shortfall, representing a transformative advance in vaccine manufacturing efficiency and safety.
Sarepta agrees to ‘painful’ pause of Elevidys shipments
July 22, 2025 / Elevidys / Duchenne muscular dystrophy / gene therapy / Sarepta Therapeutics / FDA
Sarepta has paused U.S. shipments of Elevidys, the only approved gene therapy for Duchenne muscular dystrophy, after a third patient death linked to its gene therapy platform, prompting increased FDA scrutiny.
// 4th Industrial Revolution
Aidoc Rakes In $150M for Its Clinical Decision Support AI
July 23, 2025 / clinical AI / radiology workflow / Aidoc funding / diagnostic support / patient outcomes
Aidoc raised $150M to expand its AI-powered clinical decision support platform, which streamlines radiology workflows, accelerates diagnosis, and improves care coordination across the patient journey—addressing critical challenges like radiologist shortages and emergency department overload.
Qualifacts Launches Free AI-Powered Qualifacts® iQ Assistant Across All EHR Platforms
July 23, 2025 / behavioral health / EHR assistant / AI healthcare tools / Qualifacts iQ / clinical workflows
Qualifacts launched the AI-powered iQ Assistant across its EHR platforms to streamline behavioral health workflows, reduce clinician administrative burden, and enhance care delivery—offering real-time, in-workflow support for documentation and onboarding at no cost to users.
Mayo Clinic develops AI to detect surgical site infections
July 22, 2025 / surgical infections / AI wound detection / Mayo Clinic / postoperative care / vision transformer
Mayo Clinic developed an AI model using vision transformers to detect surgical site infections from patient-submitted images with 94% accuracy, aiming to reduce clinician workload, enable earlier intervention, and improve postoperative care—especially in remote and underserved settings.
Regard Launches AI-Powered Proactive Documentation Platform, Generating Diagnosis to Save Lives
July 21, 2025 / clinical documentation / AI diagnosis / patient data / Regard platform / healthcare workflow
Regard launched an AI-powered Proactive Documentation platform that synthesizes patient chart data and conversations to generate diagnoses and clinical notes before encounters—enhancing care accuracy, streamlining workflows, and supporting revenue integrity across all hospital specialties.
Beyond the Rules Engine: How Agentic AI Is Helping Health Plans Solve Prior Authorization
July 22, 2025 / agentic AI / prior authorization / healthcare automation / clinical workflows / payer-provider efficiency
Agentic AI enables real-time, contextual automation of complex healthcare processes like prior authorization by mimicking team-based decision-making—reducing administrative burden, accelerating care delivery, and enhancing trust between payers and providers when implemented with proper governance and human oversight.
// Business & Markets
Abivax stock soars on trial data for ulcerative colitis drug
July 23, 2025 / ulcerative colitis / obefazimod / Abivax trial / IBD treatment / Phase 3 results
Abivax’s obefazimod showed strong Phase 3 efficacy in moderate-to-severe ulcerative colitis, achieving a 16.4% placebo-adjusted remission rate. With positive maintenance data expected in 2025, regulatory submissions could follow, positioning it as a leading oral IBD therapy candidate.
Talkspace, Tia Health Launch Women’s Mental Health Partnership
July 23, 2025 / women’s health / mental health care / Talkspace partnership / integrated care / Tia Health
Tia Health and Talkspace partnered to deliver integrated physical and mental health care for women, enabling seamless referrals and collaborative treatment across primary, gynecologic, and psychiatric services—addressing life-stage mental health needs like pregnancy, menopause, and hormonal shifts.
Building a Better Future Through Collaboration: How Payer-Provider Partnerships Are Transforming Healthcare
July 23, 2025 / payer-provider collaboration / value-based care / prior authorization / healthcare interoperability / administrative efficiency
Payer-provider collaborations are transforming healthcare by addressing value-based care, prior authorization, and data sharing through AI, EHR integration, and FHIR standards—yielding measurable gains in care quality, efficiency, and patient experience while reducing administrative burdens and improving outcomes.
TechMatter Acquires DoctorPapers to Expand Healthcare Revenue Cycle Management Services
July 23, 2025 / healthcare RCM / medical billing / TechMatter acquisition / revenue cycle management / healthcare automation
TechMatter acquired DoctorPapers to expand its healthcare revenue cycle management services, enhancing billing, coding, and virtual staffing capabilities. The move supports scalable, tech-enabled operations aimed at maximizing reimbursements and compliance across diverse U.S. healthcare provider settings.
Globus promotes Keith Pfeil to CEO as former exec leaves for Dentsply
July 22, 2025 / Globus Medical / CEO transition / Keith Pfeil / musculoskeletal devices / healthcare leadership
Globus Medical promoted COO/CFO Keith Pfeil to CEO after Daniel Scavilla resigned to lead Dentsply Sirona. Pfeil’s elevation ensures leadership continuity following Globus’ major spine-focused acquisitions and strong Q2 sales performance despite market uncertainty.
// Legal & Regulatory
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
July 23, 2025 / Duchenne muscular dystrophy / exon 44 skipping / delpacibart zotadirsen / FDA Breakthrough Therapy / RNA therapeutics
The FDA granted Breakthrough Therapy designation to Avidity’s delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy with exon 44 mutations, following strong Phase 1/2 results showing increased dystrophin production, exon skipping, and favorable safety ahead of a 2025 BLA submission.
Medtronic receives Type 2 label expansion for MiniMed 780G in Europe
July 23, 2025 / MiniMed 780G / Type 2 diabetes / automated insulin delivery / Medtronic CE mark / glucose control
Medtronic’s MiniMed 780G system received CE mark expansion in Europe for use in children as young as two, pregnant individuals, and those with Type 2 diabetes, supported by clinical trials showing improved A1c and time-in-range outcomes.
HHS, FDA Praise Consumer Brands Association’s Vow to Remove Artificial Colors from America’s Food Supply
July 22, 2025 / artificial food dyes / FD&C color removal / food safety / HHS FDA initiative / natural food additives
HHS and FDA praised the Consumer Brands Association’s pledge to eliminate FD&C petroleum-based artificial colors from the U.S. food supply by 2027, aiming to improve child health and promote safer, naturally colored food products across the nation.
Replimune drug rejected by FDA; Omega raises $647M biotech fund
July 22, 2025 / Replimune FDA rejection / melanoma therapy / IL-23 inhibitor / Omega biotech fund / Roche COPD trial
The FDA rejected Replimune’s melanoma drug over study design concerns, while J&J seeks approval for an oral IL-23 psoriasis drug. Omega Funds raised $647M for biotech investment, and Roche faces mixed COPD trial results for astegolimab.
FDA panel elevates concerns over antidepressant use during pregnancy
July 22, 2025 / SSRI pregnancy risks / antidepressant safety / FDA advisory panel / maternal mental health / drug labeling updates
An FDA advisory panel raised concerns about SSRI antidepressant use during pregnancy, citing potential risks and calling for stricter labeling, though no consensus was reached. Experts emphasized the need for balanced risk-benefit assessments and more targeted research in pregnant populations.
// Research & Development
SPIDR enables multiplexed mapping of RNA-protein interactions and uncovers a mechanism for selective translational suppression upon cell stress
July 22, 2025 / RNA-binding proteins / SPIDR method / translational suppression / LARP1 mTOR / RNA-protein interactions
SPIDR is a novel, high-throughput method enabling simultaneous, single-nucleotide mapping of dozens of RNA-protein interactions. It revealed LARP1’s binding to 18S rRNA at the ribosome entry site, uncovering a mechanism for selective translational suppression under mTOR-inhibited cellular stress.
Human-specific gene expansions contribute to brain evolution
July 21, 2025 / human brain evolution / gene duplications / neural development / GPR89B FRMPD2B / telomere-to-telomere genome
Using a complete human genome, researchers identified 213 human-specific gene families and 362 brain-expressed paralogs, linking genes like GPR89B and FRMPD2B to brain expansion and synapse signaling—offering key insights into the genetic drivers of human brain evolution.
Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia
July 21, 2025 / cancer cachexia / hepatokines / liver genomics / REV-ERBα / muscle wasting
Liver genomics in cancer cachexia identified hepatokines and the circadian regulator REV-ERBα as key drivers of systemic wasting. Restoring REV-ERBα reduced muscle and fat loss, highlighting the liver’s role in cachexia and revealing potential therapeutic targets.
PhoreMost demonstrates new approach to rationalize molecular glue drug discovery
July 22, 2025 / molecular glue / targeted protein degradation / GlueSEEKER platform / E3 ligase engineering / drug discovery
PhoreMost’s GlueSEEKER platform enables high-throughput, rational discovery of molecular glue degraders by engineering effector proteins like E3 ligases. The approach integrates biological data and computational tools to accelerate targeted protein degradation drug development in oncology and inflammation.
Teen bats are spawning new viruses—here’s why scientists are paying close attention
July 22, 2025 / bat coronaviruses / zoonotic spillover / viral co-infection / environmental stress / coronavirus evolution
University of Sydney researchers found that juvenile bats frequently harbor multiple coronavirus infections, increasing the likelihood of viral evolution. These findings provide a model to anticipate coronavirus emergence, especially under environmental stress and habitat loss that may drive zoonotic spillover.
// Politics
Kentucky’s campaign to improve rural cancer care is a national model. Federal cuts threaten its progress
July 23, 2025 / rural cancer care / Kentucky screenings / cancer prevention outreach / early detection programs / federal health funding
Kentucky’s grassroots cancer outreach—featuring mobile education tools and screening events—has significantly improved early detection in rural areas, serving as a national model. However, looming federal funding cuts now threaten the sustainability of these vital community-based cancer prevention programs.
RFK Jr. adopts CDC panel recommendation to remove thimerosal from flu shots
July 23, 2025 / thimerosal removal / flu vaccine preservative / RFK Jr. HHS / CDC vaccine policy / vaccine safety debate
HHS Secretary Robert F. Kennedy Jr. endorsed a CDC panel’s recommendation to remove thimerosal from multi-dose flu vaccines, despite longstanding evidence of safety. The move aligns with precautionary measures but raises concerns over vaccine access and anti-vaccine influence.
Intuitive Surgical tempers tariff impact expectations
July 23, 2025 / robotic surgery growth / da Vinci 5 launch / Intuitive Surgical forecast / U.S.-China tariffs / surgical instrument quality
Intuitive Surgical raised its 2025 procedure growth outlook amid strong da Vinci robot adoption and reduced U.S.-China tariff impact. Despite global economic pressures, broad U.S. rollout of da Vinci 5 and focus on surgical quality continue driving clinical and financial performance.
The Myth of All-American Drugs and What Trump’s Tariffs Miss About Pharma Supply Chains
July 23, 2025 / pharma tariffs impact / drug supply chain / generic drug shortages / U.S. drug manufacturing / global pharma sourcing
Pharmaceutical tariffs proposed by the Trump administration aim to reshore drug manufacturing but risk disrupting global supply chains, raising drug costs, and worsening shortages—particularly for generics—due to complex dependencies on foreign-sourced materials, infrastructure delays, and uncertain economic incentives.
Boston Scientific halves expected tariff hit
July 23, 2025 / Boston Scientific tariffs / pulsed field ablation / electrophysiology growth / Farapulse system / atrial fibrillation treatment
Boston Scientific halved its expected 2024 tariff impact to $100M while raising full-year sales guidance, driven by continued strong growth in electrophysiology, particularly in pulsed field ablation (PFA), with expanding global adoption and new indications for persistent atrial fibrillation treatment.